Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Nanomedicine. 2018 Apr 14;14(4):1381–1394. doi: 10.1016/j.nano.2018.04.008

Figure 5.

Figure 5

A. Quantification of total tumor observed in mice. Combination of cisplatin with siTWIST-MSNs reduced tumor burden 20% in comparison to cisplatin alone (P =0.1880); while combination of cisplatin with siTWIST-MSN-HA reduced this 75% (P =0.0012). B. Quantification of total metastasis observed. Cisplatin, with or without TWIST knockdown, produced a drop in tumor metastasis compared to controls (siQ and siTWIST). Addition of siTWIST led to a significant decrease (P=0.0084) when compared to cisplatin alone; while combination of cisplatin with siTWIST-MSN-HA reduced this even more (P =0.0011). C. Quantification of total ascites collected. Cisplatin, with or without TWIST knockdown, produced a drop in ascites comparing to siQ control. Addition of siTWIST led to a significant decrease (P=0.0072) when compared to cisplatin alone; while combination of cisplatin with siTWIST-MSN-HA reduced this even more (P =0.002). D. Quantification of total tumor in grams observed in mice that received therapy via intravenous (IV) versus intraperitoneal (I.P) injection. Results for both delivery vehicles are comparable.